FIC20230016I1 - Nirsevimabi - Google Patents

Nirsevimabi

Info

Publication number: FIC20230016I1
Authority: FI; Finland
Prior art keywords: nirsevimab
Prior art date: 2014-01-15

Application number

FIC20230016C

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-15

Filing date

2023-04-26

Publication date

2023-04-26

2023-04-26 Application filed filed Critical

2023-04-26 Publication of FIC20230016I1 publication Critical patent/FIC20230016I1/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FIC20230016C 2014-01-15 2023-04-26 Nirsevimabi FIC20230016I1 (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461927819P	2014-01-15	2014-01-15
PCT/US2015/011391 WO2015108967A2 (en)	2014-01-15	2015-01-14	Rsv-specific antibodies and functional parts thereof

Publications (1)

Publication Number	Publication Date
FIC20230016I1 true FIC20230016I1 (fi)	2023-04-26

Family

ID=53543612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FIC20230016C FIC20230016I1 (fi)	2014-01-15	2023-04-26	Nirsevimabi

Country Status (25)

Country	Link
US (6)	US20160340414A1 (fi)
EP (3)	EP3741390A1 (fi)
JP (4)	JP6836398B2 (fi)
KR (1)	KR102188437B1 (fi)
CN (2)	CN116355080A (fi)
AU (4)	AU2015206570A1 (fi)
CA (1)	CA2933200A1 (fi)
CY (2)	CY1123425T1 (fi)
DK (1)	DK3094353T3 (fi)
ES (1)	ES2795727T3 (fi)
FI (1)	FIC20230016I1 (fi)
FR (1)	FR23C1016I1 (fi)
HR (1)	HRP20200607T1 (fi)
HU (2)	HUE048855T2 (fi)
LT (2)	LT3094353T (fi)
MX (1)	MX374517B (fi)
NL (1)	NL301228I2 (fi)
NO (1)	NO2023016I1 (fi)
PL (1)	PL3094353T3 (fi)
PT (1)	PT3094353T (fi)
RS (1)	RS60387B1 (fi)
SI (1)	SI3094353T1 (fi)
SM (1)	SMT202000282T1 (fi)
TW (1)	TWI705974B (fi)
WO (1)	WO2015108967A2 (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
SI3094353T1 (sl)	2014-01-15	2020-07-31	Medimmune, Llc	RSY-specifična protitelesa in njihovi funkcionalni deli
US11479600B2 (en)	2016-10-21	2022-10-25	Adimab, Llc	Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TW202228779A (zh) *	2017-03-01	2022-08-01	英商梅迪繆思有限公司	抗rsv單株抗體配製物
WO2019152600A1 (en) *	2018-01-31	2019-08-08	The Wistar Institute Of Anatomy And Biology	Nucleic acid antibody constructs for use against respiratory syncytial virus
CN111606993B (zh) *	2019-02-26	2022-06-28	中国科学院上海生命科学研究院	抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en)	2019-04-30	2024-07-02	Medimmune Limited	Dosage regimens for and compositions including anti-RSV antibodies
EP4402166A2 (en)	2021-09-13	2024-07-24	MedImmune Limited	Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN119264248A (zh) *	2022-07-22	2025-01-07	北京智仁美博生物科技有限公司	抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2585891A1 (en) *	2004-10-29	2006-05-11	Medimmune, Inc.	Methods of preventing and treating rsv infections and related conditions
CA2587766A1 (en) *	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
ES2625798T3 (es)	2006-10-02	2017-07-20	E. R. Squibb & Sons, L.L.C.	Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
JP2010534057A (ja) *	2007-03-06	2010-11-04	シムフォゲン・アクティーゼルスカブ	呼吸器合胞体ウイルス感染症を治療するための組換え抗体
EP1997830A1 (en) *	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
KR20100049568A (ko) *	2007-06-26	2010-05-12	메디뮨 엘엘씨	Ｒｓｖ 감염 및 관련 병증의 치료 방법
US8092804B2 (en) *	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BRPI0906490A2 (pt)	2008-01-15	2015-07-14	Abbott Lab	Vetores de expressão de mamífero melhorados e uso dos mesmos
AU2010271583B2 (en) *	2009-07-15	2015-02-12	Kling Biotherapeutics B.V.	Means and methods for producing high affinity antibodies
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
KR101789343B1 (ko) *	2009-10-06	2017-10-23	메드임뮨 리미티드	Ｒｓｖ-특이적 결합 분자
WO2011056697A1 (en) *	2009-10-28	2011-05-12	Medimmune, Llc	Topical methods of treating rsv infections and related conditions
JP6200437B2 (ja) *	2012-03-16	2017-09-20	ユニバーシティヘルスネットワーク	Ｔｏｓｏ活性を調節するための方法および組成物
WO2013177264A1 (en) *	2012-05-22	2013-11-28	Shire Human Genetic Therapies, Inc.	Anti-ccl2 antibodies for treatment of scleroderma
DK2950886T3 (da)	2013-02-01	2020-03-23	Medimmune Llc	Respiratorisk syncytialvirus-f-protein-epitoper
SI3094353T1 (sl)	2014-01-15	2020-07-31	Medimmune, Llc	RSY-specifična protitelesa in njihovi funkcionalni deli
TW202228779A (zh)	2017-03-01	2022-08-01	英商梅迪繆思有限公司	抗rsv單株抗體配製物
JP2020509025A (ja)	2017-03-01	2020-03-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	モノクローナル抗体製剤

2015
- 2015-01-14 SI SI201531183T patent/SI3094353T1/sl unknown
- 2015-01-14 EP EP20161884.0A patent/EP3741390A1/en not_active Withdrawn
- 2015-01-14 MX MX2016008639A patent/MX374517B/es active IP Right Grant
- 2015-01-14 HU HUE15737068A patent/HUE048855T2/hu unknown
- 2015-01-14 AU AU2015206570A patent/AU2015206570A1/en not_active Abandoned
- 2015-01-14 WO PCT/US2015/011391 patent/WO2015108967A2/en active Application Filing
- 2015-01-14 CN CN202211184987.8A patent/CN116355080A/zh active Pending
- 2015-01-14 RS RS20200640A patent/RS60387B1/sr unknown
- 2015-01-14 JP JP2016541720A patent/JP6836398B2/ja active Active
- 2015-01-14 CA CA2933200A patent/CA2933200A1/en active Pending
- 2015-01-14 PL PL15737068T patent/PL3094353T3/pl unknown
- 2015-01-14 EP EP15737068.5A patent/EP3094353B1/en active Active
- 2015-01-14 HR HRP20200607TT patent/HRP20200607T1/hr unknown
- 2015-01-14 SM SM20200282T patent/SMT202000282T1/it unknown
- 2015-01-14 US US15/111,610 patent/US20160340414A1/en not_active Abandoned
- 2015-01-14 PT PT157370685T patent/PT3094353T/pt unknown
- 2015-01-14 KR KR1020167020393A patent/KR102188437B1/ko active Active
- 2015-01-14 CN CN201580003410.4A patent/CN105916520A/zh active Pending
- 2015-01-14 ES ES15737068T patent/ES2795727T3/es active Active
- 2015-01-14 DK DK15737068.5T patent/DK3094353T3/da active
- 2015-01-14 EP EP23215838.6A patent/EP4353316A3/en active Pending
- 2015-01-14 LT LTEP15737068.5T patent/LT3094353T/lt unknown
- 2015-01-15 TW TW104101373A patent/TWI705974B/zh active
2018
- 2018-06-08 US US16/003,455 patent/US10689437B2/en active Active
2020
- 2020-02-10 JP JP2020020602A patent/JP2020103293A/ja active Pending
- 2020-05-01 US US16/864,454 patent/US11186628B2/en active Active
- 2020-06-05 CY CY20201100509T patent/CY1123425T1/el unknown
- 2020-06-10 AU AU2020203831A patent/AU2020203831A1/en not_active Abandoned
2021
- 2021-06-25 AU AU2021204339A patent/AU2021204339B2/en active Active
- 2021-10-22 US US17/451,955 patent/US11661449B2/en active Active
2023
- 2023-01-27 JP JP2023010903A patent/JP2023052693A/ja active Pending
- 2023-04-18 US US18/302,400 patent/US12173050B2/en active Active
- 2023-04-25 NO NO2023016C patent/NO2023016I1/no unknown
- 2023-04-25 FR FR23C1016C patent/FR23C1016I1/fr active Active
- 2023-04-25 CY CY2023011C patent/CY2023011I1/el unknown
- 2023-04-26 FI FIC20230016C patent/FIC20230016I1/fi unknown
- 2023-04-26 NL NL301228C patent/NL301228I2/nl unknown
- 2023-04-28 LT LTPA2023514C patent/LTPA2023514I1/lt unknown
- 2023-05-02 HU HUS2300019C patent/HUS2300019I1/hu unknown
2024
- 2024-11-11 US US18/943,007 patent/US20250179153A1/en active Pending
2025
- 2025-01-09 JP JP2025003702A patent/JP2025063143A/ja active Pending
- 2025-02-14 AU AU2025201056A patent/AU2025201056A1/en active Pending

Also Published As

Publication number	Publication date
EP3094353A2 (en)	2016-11-23
US20250179153A1 (en)	2025-06-05
EP3741390A1 (en)	2020-11-25
JP2025063143A (ja)	2025-04-15
PL3094353T3 (pl)	2020-09-07
NO2023016I1 (no)	2023-04-25
SMT202000282T1 (it)	2020-07-08
RS60387B1 (sr)	2020-07-31
BR112016015044A8 (pt)	2023-04-11
JP2023052693A (ja)	2023-04-11
AU2021204339B2 (en)	2024-11-14
US12173050B2 (en)	2024-12-24
MX2016008639A (es)	2017-02-15
FR23C1016I1 (fr)	2023-06-23
DK3094353T3 (da)	2020-06-02
TW201612191A (en)	2016-04-01
LTPA2023514I1 (fi)	2023-05-25
CN116355080A (zh)	2023-06-30
US10689437B2 (en)	2020-06-23
EP3094353A4 (en)	2017-09-06
US20190106482A1 (en)	2019-04-11
HRP20200607T1 (hr)	2020-07-10
AU2025201056A1 (en)	2025-03-06
CY2023011I2 (el)	2023-11-15
BR112016015044A2 (pt)	2017-09-19
JP6836398B2 (ja)	2021-03-03
NL301228I1 (fi)	2023-05-03
HK1225992A1 (en)	2017-09-22
WO2015108967A2 (en)	2015-07-23
NL301228I2 (nl)	2023-09-13
SI3094353T1 (sl)	2020-07-31
CY1123425T1 (el)	2021-12-31
US11186628B2 (en)	2021-11-30
LT3094353T (lt)	2020-08-10
KR102188437B1 (ko)	2020-12-08
TWI705974B (zh)	2020-10-01
HUE048855T2 (hu)	2020-08-28
US20200331989A1 (en)	2020-10-22
WO2015108967A3 (en)	2015-09-03
US11661449B2 (en)	2023-05-30
JP2017504321A (ja)	2017-02-09
RU2016133247A3 (fi)	2019-01-16
MX374517B (es)	2025-03-06
CN105916520A (zh)	2016-08-31
JP2020103293A (ja)	2020-07-09
EP4353316A2 (en)	2024-04-17
CY2023011I1 (el)	2023-11-15
AU2015206570A1 (en)	2016-07-14
WO2015108967A8 (en)	2015-10-01
EP3094353B1 (en)	2020-04-01
PT3094353T (pt)	2020-06-08
US20160340414A1 (en)	2016-11-24
KR20160104018A (ko)	2016-09-02
HUS2300019I1 (hu)	2023-05-28
US20220098285A1 (en)	2022-03-31
EP4353316A3 (en)	2024-08-21
ES2795727T3 (es)	2020-11-24
US20230365660A1 (en)	2023-11-16
RU2016133247A (ru)	2018-02-20
AU2020203831A1 (en)	2020-07-02
AU2021204339A1 (en)	2021-07-22
CA2933200A1 (en)	2015-07-23

Publication	Publication Date	Title
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da)	2019-12-09	Phytasemutanter
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
EP3230438C0 (en)	2024-12-04	N-GLYCOSYLATION
NL301228I2 (nl)	2023-09-13	nirsevimab
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement
DK3009858T3 (da)	2021-08-09	Skyradar
FI20145913A (fi)	2016-04-18	Staattorimekanismi
DE112015001633A5 (de)	2017-02-23	Betätigungsaktuator
DK3447493T3 (da)	2020-08-17	Proteinrettede ortologer
ES1133830Y (es)	2015-02-12	Columbario
DK3091875T3 (da)	2019-10-14	Vipbar taburet
DK3191825T3 (da)	2019-05-06	Kreatininbiosensor
FI10894U1 (fi)	2015-06-11	Putkieristyskouru
ES1137381Y (es)	2015-06-02	Trompo
ES1136185Y (es)	2015-09-03	Huevera
FI10806U1 (fi)	2015-03-13	Ajoestepylväs
FI10861U1 (fi)	2015-04-30	Liukumisenestonasta